Anticholinergic bladder drugs were associated with an increased risk of dementia compared with nonuse, but not when compared with the beta-3 agonist mirabegron.
The BrainSense Adaptive deep brain stimulation system is the first FDA-approved closed-loop neuromodulation therapy designed to automatically adjust stimulation in real time based on individual brain activity for patients with Parkinson’s disease.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The U.S. Food and Drug Administration has approved Onapgo, a continuous apomorphine hydrochloride infusion, for the treatment of motor fluctuations in adult patients with advanced Parkinson’s disease.
New study reveals that epigenetic age predictions fluctuate significantly throughout the day, emphasizing the need to consider timing in aging assessments.